Fecal Calprotectin Testing Market Analysis

  • Report ID: 4060
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Fecal Calprotectin Testing Market Analysis

End-user (Hospitals, Diagnostic Laboratories, Academics, Research Institutes)

The global fecal calprotectin testing market is segmented and analyzed for demand and supply by end-user into hospitals, diagnostic laboratories, academics, research institutions, and others. Amongst these segments, the hospital segment is expected to garner a significant share. The growth of the segment can be attributed to the rapid escalation of patient flow in the hospitals and increasing spending on healthcare across the globe as a result of increasing cases of gastrointestinal diseases, digestive disorders, and intestine illnesses being diagnosed on an everyday basis. As per the health expenditure report shared by the World Bank, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000) across the globe.

Disease Type (Inflammatory Bowel Disease, Colorectal Cancer, Celiac Disease)

The global fecal calprotectin testing market is also segmented and analyzed for demand and supply by disease type into inflammatory bowel disease owing to the rising cases of chronic inflammation of tissues in the digestive tract. High consumption of junk, oily food items, packaged food, and others have propelled the growth of inflammatory bowel disease among the population which is estimated to create a positive outlook for segment growth during the analysis period. The Centers for Disease Control and Prevention (CDC) estimated that around 3 million people present in the North American region have been diagnosed with inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis in 2020. On the other hand, the colorectal cancer segment is also attributed to garnering a significant market share owing to the high prevalence of colon and rectum cancer among the population which generates the demand for fecal calprotectin testing for proper diagnosing and treatment procedures. 

Our in-depth analysis of the global market includes the following segments:

        By Disease Type

  • Inflammatory Bowel Disease
  • Colorectal Cancer
  • Celiac Disease
  • Others

        By Patient Type

  • Geriatric
  • Pediatric
  • Adult

          By End User

  • Hospitals
  • Diagnostic Laboratories
  • Academics
  • Research Institutes
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4060
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of fecal calprotectin testing is assessed at USD 158.24 million.

The fecal calprotectin testing market size was valued at USD 145.44 million in 2024 and is set to reach USD 473.1 million by the end of 2037, expanding at around 10.9% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of colorectal cancer and other gastrointestinal diseases will boost the market growth.

North America is projected to hold the largest industry share by 2037, propelled by increasing frequency of colorectal cancer, celiac disease, and other disorders in developed countries.

The major players in the market include Exelixis Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample